Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy.
a Department of Hematology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China.
Xin-Xin
XX
Cao
b Department of Dermatology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China.
Tao
T
Wang
b Department of Dermatology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China.
Yue-Hua
YH
Liu
a Department of Hematology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China.
Dao-Bin
DB
Zhou
a Department of Hematology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China.
Jian
J
Li
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D060046:Maintenance Chemotherapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D010265:Paraproteinemias / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D053718:Scleromyxedema / Q000188:drug therapy* / Q000209:etiology; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
D007074:Immunoglobulin G; D013792:Thalidomide; D003907:Dexamethasone; D008558:Melphalan